Welcome
Support Centre
30 September 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
DRN 725: Chronic Disease Resource Centre Diabetes Division
ISRCTN ISRCTN17526370
DOI 10.1186/ISRCTN17526370
ClinicalTrials.gov identifier
EudraCT number
Public title DRN 725: Chronic Disease Resource Centre Diabetes Division
Scientific title Chronic Disease Resource Centre: What is the natural history of diabetes and its complications?
Acronym N/A
Serial number at source 12984
Study hypothesis The aim of this study is to establish a prospective, observational multi-ethnic cohort of adult participants diagnosed with impaired glucose tolerance. The cohort will encourage academic collaboration for patient benefit and will be characterised by anthropometry, questionnaires, biological samples and co-morbidities forming a resource for epidemiological, clinical and health service research.

The study will aim to recruit all eligible participants from across the West Midlands Birmingham area. A 10 year study will be undertaken to recruit and follow-up 1000 participants, concentrating initially on University Hospitals Birmingham NHS Foundation Trust (UHBFT), before but could be opening to other NHS clinical centres trusts interested in collaborating.

In addition to providing information about the natural history and progression of diabetes, development of complications and co-morbidities it will provide unique information for use in the detection of biomarkers to help predict the progression of complications and to monitor the effectiveness of interventions.

Also, the study will try to accurately categorise patients with potentially different types of diabetes in order to determine whether any factors significantly affect their long-term morbidity or mortality.

In summary the overarching aims and objectives of this study is:
1. To understand the natural history of diabetes in our local population. To determine the incidence of other chronic medical conditions in patients with diabetes.
2. Provide a repository of information for future analysis to help determine potential biomarkers of chronic diseases related to diabetes.

More details can be found at: http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=12984
Lay summary Background and study aims
The study aims to recruit individuals with diabetes or a pre-diabetic condition. We will collect information and blood samples from patients once a year at a time convenient to the individual and the research team (normally at the same time as their annual diabetes check). The information collected from this study will be used in research into how diabetes affects individuals in the setting of it being a chronic disease. The aim of this study is to establish a database of information of adult participants diagnosed with impaired glucose tolerance. This database will be used to explore the psycho-social aspects of diabetes in the context of it being a chronic disease. Also, the database will be used to develop partnerships with other researchers to advance diabetes research for the benefit of individuals with diabetes.

Who can participate?
Individuals who are 18 years or older with confirmed diabetes or abnormal glucose tolerance. Individuals must be willing and able to attend annual appointments at clinical study recruitment site centre.

What does the study involve?
The study involves an annual study visit where non-invasive clinical measurements will be taken, along with a questionnaire, blood and urine samples.

What are the possible benefits and risks of participating?
As this study is does not involve any intervention then the risks to participants are minimal.

Where is the study run from?
The study is currently run from the Queen Elizabeth Hospital Birmingham, UK. There is a network of other centres throughout the West Midlands who are also participating in this study.

When is the study starting and how long is it expected to run for?
The study started in September 2012 and is expected to run until April 2022.

Who is funding the study?
Novo Nordisk A/S (USA)

Who is the main contact?
Jayne Robbie
Diabetes Research Unit
Nuffield House
Queen Elizabeth Hospital
Birmingham B15 2TH
UK
Ethics approval NRES Committee West Midlands - Staffordshire, 8th May 2012, ref: 12/WM/0089
Study design Non-randomised observational cohort study
Countries of recruitment United Kingdom
Disease/condition/study domain Diabetes Research Network
Participants - inclusion criteria 1. Male or female, age >= 18 years
2. Confirmed diagnosis of diabetes or prediabetes
3. Individuals freely able to attend appointments at the Chronic Disease Research Centre
4. Individuals who are able to undergo the appropriate investigations
Participants - exclusion criteria 1. Individuals unable to attend for research visits
2. Individuals who in the clinicians opinion is not appropriate for recruitment into this study
Anticipated start date 06/09/2012
Anticipated end date 01/04/2022
Status of trial Ongoing
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants UK Sample Size: 1000
Interventions The study is observing changes in participants with diabetes in several domains: depression, quality of life, eating behaviour, risk of sleep apnoea, activities of daily living, employment and productivity, as well as developing a repository of biological samples. The tests will include routine clinical assessment, bone, liver, renal, thyroid blood tests, and questionnaires. Patients will also be invited to undertake more significant testing including analysis of saliva samples, AGE reader, pancreatic stimulation tests.
Primary outcome measure(s) Micro and macro vascular complications measured at 10 years
Secondary outcome measure(s) Qualitative and questionnaire based assessment of diabetes related endpoints measured at 10 years
Sources of funding Novo Nordisk A/S (UK)
Trial website
Publications
Contact name Dr  Parth  Narendran
  Address University of Birmingham
Institute of Biomedical Research
Division of Immunity and Infection
Medical School
Edgbaston
  City/town Birmingham
  Zip/Postcode B15 2TT
  Country United Kingdom
  Email p.narendran@bham.ac.uk
Sponsor University of Birmingham (UK)
  Address Department of Primary Care & General Practice
Primary Care Clinical Sciences Building
Edgbaston
  City/town Birmingham
  Zip/Postcode B15 2TT
  Country United Kingdom
  Sponsor website: http://www.birmingham.ac.uk/
Date applied 19/11/2012
Last edited 27/03/2013
Date ISRCTN assigned 27/03/2013
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.